Pan-India IVF and fertility-care chain operating a hub-and-spoke network of clinics with AI-assisted embryology, offering IVF treatment, hospital care and pharmacy services under the Gaudium IVF brand.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 19.4 | +9.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 12.5 | −16.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.8 | −42.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 23.27 | −27.3 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 0.00 | 0.0 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | −1.4 pts | Trailing twelve months | TTM to Jun 2026 | Not in the analysed materials. No older figure is substituted. |
Guidance
0 of 2 judged targets kept · 10 open · verdicts reflect calls analysed to Q1 FY27.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| New International Spokes | 3 international spokes (Paris, Nigeria, Sydney) to be added this quarter | Q4 FY26 | Management mentioned they are 'establishing' three international spokes in Paris, Nigeria, and Sydney, but did not confirm if they were added in Q1 FY27 as originally promised. | Ghosted |
| New IVF Hubs (Total) | 19 new IVF hubs planned under IPO use of proceeds | Q4 FY26 | Reiterated the plan for 19 hubs (10 in FY27, 8 in FY28, 1 in FY29) and made the first one (South Extension) operational on July 16, 2026. | On Track |
2 of Gaudium IVF and Women Health Limited's 12 targets were missed. See which ones, and which are quietly gone. The 2 above are the free sample; 10 more targets are in the full ledger.
Claimed
Qualified
Price
YTD: ₹80.26 on 27 Feb 2026 → ₹98.77. High ₹158.16 (22 Jul 2026), low ₹70.67 (23 Mar 2026).
Overview
Based on the company's own presentations, annual report and earnings calls.
Gaudium IVF and Women Health Limited runs fertility clinics under the Gaudium IVF brand, delivering IVF treatment along with hospital and pharmacy services through a hub-and-spoke network of comprehensive-care hubs and smaller spoke centres across India. Patients move through a structured, SOP-driven pathway — registration, ovulation induction, ovum pick-up, embryo transfer, and post-transfer care — supported by embryology labs, andrology labs, surgical suites and cryo-storage facilities at each hub. The company also serves international patients, including from the Middle East, UK, Africa, Australia, New Zealand, Canada and Indonesia, and has deployed proprietary AI tools (SiD for sperm selection, ERICA for embryo ranking) to support clinical decision-making.
Segments
close before → close after
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Guidance
0 of 2 judged targets kept · 10 open · verdicts reflect calls analysed to Q1 FY27.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| New International Spokes | 3 international spokes (Paris, Nigeria, Sydney) to be added this quarter | Q4 FY26 | Management mentioned they are 'establishing' three international spokes in Paris, Nigeria, and Sydney, but did not confirm if they were added in Q1 FY27 as originally promised. | Ghosted |
| New IVF Hubs (Total) | 19 new IVF hubs planned under IPO use of proceeds | Q4 FY26 | Reiterated the plan for 19 hubs (10 in FY27, 8 in FY28, 1 in FY29) and made the first one (South Extension) operational on July 16, 2026. | On Track |
Claimed
Qualified
The full ledger
A free account opens 5 company ledgers a month. All 12 tracked commitments, with each call’s wording and source.
Call summaries
Gaudium IVF and Women Health Limited Q1 FY27
Gaudium IVF and Women Health Limited reported a 9.1% YoY revenue growth to ₹19.4 crores in Q1 FY27. However, profitability metrics like EBITDA and PAT saw significant moderation due to strategic investments in new AI technology and pre-operational costs for new centers. The company remains confident in its full-year targets, driven by its expansion roadmap, clinical excellence, and debt-light balance sheet.
Read the full callGAUDIUMIVF Q4 FY26
Gaudium IVF reported strong financial performance for Q4 and FY26, with significant YoY growth in revenue, EBITDA, and PAT. The company successfully completed its IPO, raising approximately INR 165 crore, and is now debt-light, positioning it for aggressive expansion. Strategic initiatives include integrating AI-led embryology for improved success rates and expanding its hub-and-spoke model, alongside efforts to enhance affordability and manage trade receivables.
Read the full callEvery analysed call
Fundamentals
Current values with the period they cover; the trend reads across the 5 fiscal years held (Mar 2022 to Mar 2026).
Financials
Net profit, year on year: −42% (quarter to jun 2026 against jun 2025).
| Line item | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 14 | 27 | 18 | 32 | 25 | 30 | 19 |
| Expenses | 9 | 18 | 13 | 18 | 18 | 18 | 17 |
| Operating profit | 6 | 9 | 5 | 14 | 7 | 12 | 2 |
| Operating margin | 39.3% | 32.4% | 29.0% | 43.4% | 26.8% | 40.1% | 12.5% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| Depreciation | 1 | 0 | 1 | 1 | 0 | 1 | 1 |
| Profit before tax | 5 | 8 | 4 | 13 | 5 | 10 | 2 |
| Tax rate | 27.7% | 21.0% | 24.0% | 26.6% | 27.0% | 19.8% | 27.8% |
| Net profit | 3 | 6 | 3 | 9 | 4 | 8 | 2 |
| EPS (₹ per share) | 0.55 | 1.05 | 0.50 | 1.53 | 0.59 | 1.15 | 0.24 |
| Line item | Mar 2026 |
|---|---|
| Sales | 104 |
| Expenses | 67 |
| Operating profit | 38 |
| Other income | 0 |
| Interest | 4 |
| Depreciation | 2 |
| Profit before tax | 32 |
| Net profit | 24 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 31 | 31 | 36 |
| Reserves | 8 | 22 | 26 | 16 | 28 | 116 |
| Borrowings | 6 | 12 | 17 | 21 | 24 | 25 |
| Other liabilities | 3 | 2 | 7 | 22 | 24 | 16 |
| Total liabilities | 18 | 37 | 51 | 89 | 107 | 193 |
| Fixed assets | 4 | 18 | 19 | 18 | 30 | 18 |
| Capital work in progress | 0 | 0 | 0 | 7 | 0 | 12 |
| Investments | 0 | 0 | 0 | 5 | 5 | 5 |
| Other assets | 14 | 18 | 32 | 58 | 72 | 158 |
| Total assets | 18 | 37 | 51 | 89 | 107 | 193 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operations | -1 | 24 | 3 | 9 | 7 |
| Cash from investing | -1 | -16 | -5 | -15 | -88 |
| Cash from financing | 3 | 5 | -1 | 2 | 82 |
| Net cash flow | 0 | 13 | -3 | -5 | 2 |
| Free cash flow | -2 | 9 | 1 | 0 | 1 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor days | 65 | 8 | 104 | 170 | 187 |
| Inventory days | 29 | 111 | 168 | 175 | 38 |
| Days payable | 114 | 77 | 62 | 344 | 133 |
| Cash conversion cycle | -20 | 41 | 210 | 1 | 92 |
| Working capital days | 61 | -52 | -15 | 44 | 91 |
| Return on capital employed | — | 76.0% | 45.0% | 49.0% | 30.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Promoters hold 71.29% as of Sept 2026; institutions cut 1.82 pts since Jun 2026.
Named in the Sep 2026 filing
Every holder of Gaudium IVF and Women Health Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 70.73% | unchanged | |
| 4.26% | unchanged | |
| 3.43% | unchanged | |
| AIF | 1.79% | unchanged |
| 1.28% | unchanged | |
| 0.30% | unchanged | |
| 0.26% | unchanged | |
| 0.01% | unchanged | |
| FPI fund | — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Free account: one company. Everything above stays public.
Write why you follow Gaudium IVF and Women Health Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Guides on how to read this kind of business and the numbers that matter.
